Actively Recruiting
Phase 3 Study Comparing GZR33 Injection and Insulin Degludec in Adults with Type 2 Diabetes Not Controlled by Oral Medications
Led by Gan & Lee Pharmaceuticals. · Updated on 2026-07-01
350
Participants Needed
1
Research Sites
53 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of once-daily GZR33 Injection compared to once-daily Insulin Degludec Injection Tresiba in adults with Type 2 Diabetes Mellitus who are not adequately controlled with oral antidiabetic drugs. This Phase 3 trial aims to determine which treatment better manages blood sugar levels in this population. Participants will be randomly assigned to receive either the GZR33 Injection or Insulin Degludec Injection, both administered once daily under the skin. The study treatment period lasts 26 weeks, during which participants will adhere to their assigned medication and follow lifestyle guidelines. The trial is designed to directly compare these two insulin therapies. Throughout the study, participants will undergo regular assessments including measurements of Hemoglobin A1c HbA1c and fasting plasma glucose to monitor blood sugar control. Safety and treatment adherence will also be evaluated. The total participation duration covers the 26-week treatment phase, with researchers focusing on changes in HbA1c from the start to the end of this period.
CONDITIONS
Brief Title
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
Research Team
Y
Yuchi Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
